Search

everythinglearnresearchcommunity

for

Search:↓

PEVIII is a promising treatment for Pseudomonas aeruginosa keratitis.

Topical calcitriol may reduce hair loss from chemotherapy at higher doses.

MK-5108 is safe and shows potential against tumors, especially alone.

Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.

TYK2 inhibitors show promise for treating cancer and autoimmune disorders.

Baricitinib is a promising treatment for alopecia areata.

Leflunomide and anthralin may effectively treat severe alopecia areata.

Interferon, especially alfa interferon, is an effective treatment for cutaneous T-cell lymphoma with manageable side effects.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

The rash resolved after stopping ponatinib.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

Chemotherapy-induced hair loss may be linked to immune system changes, and certain treatments could help but need careful use.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

Enhancing Tregs can protect against alopecia areata.

New compounds may help treat heart disease by activating specific potassium channels.

Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.

Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.

Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

Tofacitinib effectively improved severe skin symptoms in a patient with Hypohidrotic Ectodermal Dysplasia.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.

Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Rapamycin may help treat Leigh syndrome by targeting protein kinase C.

The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.